Literature DB >> 11174133

Radiotherapy of recurrent basal and squamous cell skin carcinomas: a study of 249 re-treated carcinomas in 229 patients.

M Caccialanza1, R Piccinno, A Grammatica.   

Abstract

It is of great practical utility to assess which is the best therapeutic choice in the management of basal and squamous cell skin carcinomas recurring after different treatments (RBSCSC). To this aim, we have performed a retrospective review of 249 recurrent lesions in 229 patients treated with dermatological radiotherapy in the period 1982-1999. The total doses of ionizing radiations administered ranged from 45 to 70 Gy, with different dose fractionations, according to the technique employed. The five-year cure-rate was 83.62%. Cosmetic results were evaluated as "good" or "acceptable" in 92.62% of the treated lesions in complete remission. So far no complications or sequelae to the radiological treatment have been observed. Our results suggest two considerations about the choice in the treatment of RBSCSC (following non radiological therapies): 1. radiotherapy is a safe treatment and the most effective after Mohs surgery; 2. radiotherapy is a first-line treatment in those patients who cannot undergo extensive surgery for a variety of different reasons (age, general health conditions, etc.).

Entities:  

Mesh:

Year:  2001        PMID: 11174133

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  2 in total

Review 1.  Preventing complications in dermatologic surgery: Presurgical concerns.

Authors:  Allen G Strickler; Payal Shah; Shirin Bajaj; Richard Mizuguchi; Rajiv I Nijhawan; Mercy Odueyungbo; Anthony Rossi; Désirée Ratner
Journal:  J Am Acad Dermatol       Date:  2021-01-23       Impact factor: 15.487

2.  Utilization of a 3D printer to fabricate boluses used for electron therapy of skin lesions of the eye canthi.

Authors:  Magdalena Łukowiak; Karolina Jezierska; Marek Boehlke; Marzena Więcko; Adam Łukowiak; Wojciech Podraza; Mirosław Lewocki; Bartłomiej Masojć; Michał Falco
Journal:  J Appl Clin Med Phys       Date:  2016-11-30       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.